Status:

UNKNOWN

Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?

Lead Sponsor:

Bassem Mohamed Sieda

Conditions:

Papillary Thyroid Carcinoma

Eligibility:

All Genders

42-55 years

Phase:

NA

Brief Summary

study assigned into three groups, Group I was the control group operated by total thyroidectomy and retrospectively followed, where the other two groups Operated by Total thyroidectomy and central nec...

Detailed Description

informed consent taken, study was a prospective cohort study, with controlled group a retrospectively. patients ablated by total thyroidectomy only who failed to achieve ablation with the first dose o...

Eligibility Criteria

Inclusion

  • Age ≥20 years, Histopathology proved PTC, with no lymph nodes detected (N0)

Exclusion

  • Younger age ≤20 years. Prior thyroidectomy, previous radiation exposure, postoperative radioactive iodine therapy, Histopathology report of any type of malignancy other than PTC or patients did not complete their postoperative follow-up period. PTC With N1 or N2

Key Trial Info

Start Date :

November 2 2016

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 3 2020

Estimated Enrollment :

199 Patients enrolled

Trial Details

Trial ID

NCT04336696

Start Date

November 2 2016

End Date

May 3 2020

Last Update

April 7 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zagazig University Hospitals

Zagazig, Egypt, 13

Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0? | DecenTrialz